{"filing":{"accession_number":"0001493152-26-030205","cik":"0002010788","ticker":"EXOZ","company_name":"EXOZYMES INC.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/form8-k.htm"},"events":[{"id":14069,"run_id":12507,"accession_number":"0001493152-26-030205","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"eXoZymes announced receipt of a $2 million NIH Phase IIB SBIR grant to advance cannabinoid analogs for drug discovery, representing non-dilutive funding that validates the company's platform and expands its pipeline. This is a material operational and strategic milestone—the grant funds a two-year research program, brings total non-dilutive funding to $19.7 million, and demonstrates the company's ability to develop a second biosolution (after NCT) with potential for future licensing and partnership opportunities. While not a traditional M\u0026A, litigation, or financial event, the grant is material to investors assessing the company's development trajectory and competitive position in the cannabinoid therapeutics space.","company_name":"EXOZYMES INC.","ticker":"EXOZ","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11398,"accession_number":"0001493152-26-030205","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"eXoZymes announced receipt of a $2 million NIH Phase IIB SBIR grant to advance cannabinoid analogs for drug discovery, representing non-dilutive funding that validates the company's platform and expands its pipeline. This is a material operational and strategic milestone—the grant funds a two-year research program, brings total non-dilutive funding to $19.7 million, and demonstrates the company's ability to develop a second biosolution (after NCT) with potential for future licensing and partnership opportunities. While not a traditional M\u0026A, litigation, or financial event, the grant is material to investors assessing the company's development trajectory and competitive position in the cannabinoid therapeutics space.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:05:49.296792+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11398,"accession_number":"0001493152-26-030205","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"eXoZymes announced receipt of a $2 million NIH Phase IIB SBIR grant to advance cannabinoid analogs for drug discovery, representing non-dilutive funding that validates the company's platform and expands its pipeline. This is a material operational and strategic milestone—the grant funds a two-year research program, brings total non-dilutive funding to $19.7 million, and demonstrates the company's ability to develop a second biosolution (after NCT) with potential for future licensing and partnership opportunities. While not a traditional M\u0026A, litigation, or financial event, the grant is material to investors assessing the company's development trajectory and competitive position in the cannabinoid therapeutics space.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:05:49.296792+00:00","company_name":"EXOZYMES INC.","ticker":"EXOZ","filing_date":"2026-06-25"}]}